petition from t315i patients on the web, page-11

biotrek,

Just a small correction, no one is claming 15-20% of the total CML population....it's 15-20% of those that stop responding to 1st line treatment (which after 5 years treatment is around 40%) are t315i related. 2nd line treatments when having t315i worsen the outcome or are useless.

Anyways, the stock price is worth far more than the current value. The real market value in time, I have no idea.

"15-20% of t315i mutations would mean (15-20% x 5000) = 750-1000 new t315i patients per year in USA. "